Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0025 + Chemotherapy in Advanced Solid Tumors
NCT06758557Phase 2Recruiting
- Sponsor
- Huabo Biopharm
- Start
- Jan 2024
- Primary completion
- Oct 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sotiburafusp alfa in non-small cell lung cancer (NSCLC), endometrial cancer (EC), sponsored by Huabo Biopharm. Started Jan 2024; status: recruiting.
02
Drugs
sotiburafusp alfa
03
Conditions
non-small cell lung cancer (NSCLC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06758557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06758557.